Baxter International BAX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| Healthcare Systems & Technologies | $3.07B+4.1% | $2.95B-2.1% | $3.01B— | —— | |
| Medical Products & Therapies | $5.3B+1.8% | $5.21B+3.9% | $5.01B— | —— | |
| Pharmaceuticals | $2.49B+3.4% | $2.41B+7.2% | $2.25B— | —— | |
| Segment operating income by Business | |||||
| Healthcare Systems & Technologies | $441M-5.8% | $468M-3.1% | $483M— | —— | |
| Medical Products & Therapies | $970M+2.1% | $950M-2.3% | $972M— | —— | |
| Pharmaceuticals | $222M-29.1% | $313M-21.9% | $401M— | —— | |
| Reportable Segment | $1.63B-5.7% | $1.73B-6.7% | $1.86B+165% | -$2.85B— | |
| Other segment items by Business | |||||
| Healthcare Systems & Technologies | -$36M-3,500% | -$1M— | $0— | $0— | |
| Medical Products & Therapies | -$107M— | —— | $0+100% | -$2M— | |
| Pharmaceuticals | -$36M-3,500% | -$1M0.0% | -$1M— | $0— | |
| Currency translation and other by Business | |||||
| Healthcare Systems & Technologies | $22M+257% | -$14M-1,500% | $1M+103% | -$35M— | |
| Medical Products & Therapies | $80M+243% | -$56M-222% | $46M— | $0— | |
| Pharmaceuticals | $37M+261% | -$23M-210% | $21M— | $0— | |
| Selling, general and administrative expenses by Business | |||||
| Healthcare Systems & Technologies | $873M+4.4% | $836M+1.7% | $822M-0.6% | $827M— | |
| Medical Products & Therapies | $1.16B-1.2% | $1.18B+7.2% | $1.1B+2.6% | $1.07B— | |
| Pharmaceuticals | $429M+8.3% | $396M+9.1% | $363M+0.6% | $361M— | |
| Research and development expenses by Business | |||||
| Healthcare Systems & Technologies | $190M+3.3% | $184M+4.5% | $176M+13.5% | $155M— | |
| Medical Products & Therapies | $209M-3.2% | $216M-2.7% | $222M+9.9% | $202M— | |
| Pharmaceuticals | $101M+11.0% | $91M+5.8% | $86M+6.2% | $81M— | |
| Cost of Sales by Business | |||||
| Healthcare Systems & Technologies | $1.6B+9.5% | $1.46B-4.4% | $1.53B+4.7% | $1.46B— | |
| Medical Products & Therapies | $3.07B+6.9% | $2.87B+5.4% | $2.72B+5.3% | $2.58B— | |
| Pharmaceuticals | $1.78B+10.2% | $1.61B+15.1% | $1.4B+8.3% | $1.29B— | |
| Goodwill by Business | |||||
| Healthcare Systems & Technologies | $13.79B-11.1% | $15.5B— | —— | —— | |
| Medical Products & Therapies | $5B+3.6% | $4.83B— | —— | —— | |
| Pharmaceuticals | $2.28B+3.9% | $2.19B— | —— | —— | |
| Depreciation by Business | |||||
| Healthcare Systems & Technologies | $112M+2.8% | $109M+0.9% | $108M-7.7% | $117M+3,800% | |
| Medical Products & Therapies | $206M+2.5% | $201M-13.4% | $232M+6.9% | $217M+1.9% | |
| Pharmaceuticals | $65M+4.8% | $62M+14.8% | $54M-8.5% | $59M-16.9% | |
| Net Sales by Product | |||||
| Advanced Surgery | $1.2B+8.5% | $1.1B+5.0% | $1.05B+5.3% | $998M+2.1% | |
| Care & Connectivity Solutions | $1.91B+5.3% | $1.81B+0.7% | $1.8B— | —— | |
| Drug Compounding | $1.14B+9.9% | $1.04B+15.1% | $902M— | —— | |
| Front Line Care | $1.16B+2.0% | $1.14B-6.2% | $1.21B+5.6% | $1.15B+1,540% | |
| Infusion Therapies & Technologies | $4.1B0.0% | $4.1B+3.6% | $3.96B— | —— | |
| Injectables & Anesthesia | $1.35B-1.5% | $1.37B+1.9% | $1.35B— | —— | |
| Net Sales by Geography | |||||
| International | $5.12B+7.0% | $4.79B-22.3% | $6.16B— | —— | |
| United States | $6.12B+4.6% | $5.85B-8.4% | $6.39B+9.8% | $5.81B+17.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Baxter International break its business down?
- Baxter International (BAX) reports net sales by business across 3 parts — Healthcare Systems & Technologies, Medical Products & Therapies and Pharmaceuticals. Each is extracted from the segment footnotes and tracked over time.
- Where does Baxter International's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Baxter International's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
